Mikko Gynther

Publications44
h-index16
Citations844
Highly Influential Citations27
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • K. Huttunen
  • 90 Publications, 1,846 Citations
  • Y. Kanai
  • 338 Publications, 18,831 Citations
  • J. Rautio
  • 93 Publications, 3,514 Citations
  • H. Endou
  • 458 Publications, 21,586 Citations
  • Publications
  • Influence
Prodrug Approaches for CNS Delivery
Central nervous system (CNS) drug delivery remains a major challenge, despite extensive efforts that have been made to develop novel strategies to overcome obstacles. Prodrugs are bioreversible… Expand
  • 102
  • 6
  • PDF
Large neutral amino acid transporter enables brain drug delivery via prodrugs.
The blood-brain barrier efficiently controls the entry of drug molecules into the brain. We describe a feasible means to achieve carrier-mediated drug transport into the rat brain via the specific,… Expand
  • 130
  • 5
Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats.
The brain uptake of solutes is efficiently governed by the blood-brain barrier (BBB). The BBB expresses a number of carrier-mediated transport mechanisms, and new knowledge of these BBB transporters… Expand
  • 74
  • 3
LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier?
  • 22
  • 3
Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
Central nervous system (CNS) drug delivery is a major challenge in drug development because the blood-brain barrier (BBB) efficiently restricts the entry of drug molecules into the CNS at sufficient… Expand
  • 62
  • 1
Brain uptake of ketoprofen-lysine prodrug in rats.
The blood-brain barrier (BBB) controls the entry of xenobiotics into the brain. Often the development of central nervous system drugs needs to be terminated because of their poor brain uptake. We… Expand
  • 53
  • 1
Quantitative Insight into the Design of Compounds Recognized by the L‐Type Amino Acid Transporter 1 (LAT1)
L‐Type amino acid transporter 1 (LAT1) is a transmembrane protein expressed abundantly at the blood–brain barrier (BBB), where it ensures the transport of hydrophobic acids from the blood to the… Expand
  • 32
  • 1
A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
The l-type amino acid transporter 1 (LAT1) is a transmembrane protein carrying bulky and neutral amino acids into cells. LAT1 is overexpressed in several types of tumors, and its inhibition can… Expand
  • 33
  • 1
UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: Comparison with the NMDA receptor antagonist MK-801
Excessive N-Methyl-d-aspartate receptor (NMDAR)-dependent production of nitric oxide (NO) is involved in the development and maintenance of chronic pain states, and is mediated by postsynaptic… Expand
  • 20
  • 1
Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests
Monoamine-based antidepressant drugs increase α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) function and decrease N-methyl-d-aspartate receptor (NMDAR) function. The NMDAR… Expand
  • 27
  • 1